NCT06128278RecruitingPhase 2
Acute Equol Supplementation and Vascular Function in Women With and Without CKD
Acute Equol Supplementation and Vascular Function in Postmenopausal Women With and Without CKD
Source: ClinicalTrials.gov · Last updated 30 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH. Equol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the acute effect (1-hour, 2-hours, and 3-hours post ingestion) of oral equol supplementation on vascular function in postmenopausal women with and without CKD.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- First submitted
- 7 Nov 2023
- Start date
- 7 Mar 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of Colorado, Denver
- Diseases
- Chronic kidney disease
- NCT number
- NCT06128278
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 38
- From 7 Mar 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of HRT or has used HRT for \<6 months prior to enrollment
- Antioxidant and/or omega-3 fatty acid use within the 2 weeks prior to testing
- Marijuana use within 2 weeks prior to testing
- Consumption of soy and soy-based products 3 days prior to testing
Other illness
- History of kidney transplant
- Use of immunosuppressant medications (unless taking a stable dosage for a quiescent disease)
- Current tobacco or nicotine use or history of use in the last 12 months
- Uncontrolled hypertension in CKD group (BP\>140/90 mmHg)
- Active infection or antibiotic therapy
Other
- Advanced CKD requiring dialysis
- Atrial fibrillation
- Hospitalization in the last month
Who the study is looking for
- Postmenopausal (50-69 y) women
- Women with CKD including stage 3-4 (eGFR 15-59 ml/min/1.73m2) determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 equation
- Women without CKD (eGFR \>60 ml/min/1.73m2) must be healthy (free from hypertension, kidney disease, CVD, diabetes, and other chronic disease as assessed by self-report, medical history, and screening labs).
Age in the registry: 50 years to 69 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Colorado Anschutz Medical Campus Coordinator of this site? Confirm its status | Aurora | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.